Hikma steps up $250m buyback, cancels further shares

Hikma Pharmaceuticals ( (GB:HIK) ) has shared an update.

Hikma Pharmaceuticals has continued executing its previously announced $250 million share repurchase programme, buying back 140,777 ordinary shares on the London Stock Exchange between 7 and 9 April 2026 at volume‑weighted average prices around 1,283 to 1,306 pence. The company plans to cancel these shares, bringing total buybacks since the programme’s launch to 4.13 million shares at a cost of £51.6 million, and leaving 217.75 million ordinary shares in issue and an equivalent number of voting rights, a move that incrementally enhances earnings per share and signals ongoing capital returns to shareholders.

The most recent analyst rating on (GB:HIK) stock is a Buy with a £1800.00 price target. To see the full list of analyst forecasts on Hikma Pharmaceuticals stock, see the GB:HIK Stock Forecast page.

Spark’s Take on HIK Stock

According to Spark, TipRanks’ AI Analyst, HIK is a Neutral.

The score is held back primarily by weakening cash generation and a notably bearish technical trend (oversold and trading below key moving averages). These are partially offset by attractive valuation (low P/E and strong dividend yield) and a constructive earnings-call outlook supported by guidance comfort and a GBP 250m buyback, despite near-term injectable headwinds.

To see Spark’s full report on HIK stock, click here.

More about Hikma Pharmaceuticals

Hikma Pharmaceuticals is a multinational generic and specialty pharmaceuticals company listed in London and on Nasdaq Dubai. The group develops, manufactures and markets a broad portfolio of injectable and oral medicines, with a particular focus on complex generics and branded products for hospitals and healthcare systems across global markets.

Average Trading Volume: 1,397,768

Technical Sentiment Signal: Sell

Current Market Cap: £2.86B

See more data about HIK stock on TipRanks’ Stock Analysis page.